January 25, 2018Open Access
View Full PaperTrial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Key Points
Key points are not available for this paper at this time.
Abstract
Solanezumab at a dose of 400 mg administered every 4 weeks in patients with mild Alzheimer's disease did not significantly affect cognitive decline. (Funded by Eli Lilly; EXPEDITION3 ClinicalTrials.gov number, NCT01900665 .).